{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06343402",
            "orgStudyIdInfo": {
                "id": "TBBO8520-101"
            },
            "secondaryIdInfos": [
                {
                    "id": "ONKORAS-101",
                    "type": "OTHER",
                    "domain": "TheRas"
                }
            ],
            "organization": {
                "fullName": "TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer",
            "officialTitle": "A Phase 1a/1b Open-Label Study of BBO-8520 Monotherapy and BBO-8520 in Combination With Pembrolizumab in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - the ONKORAS-101 Study",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "study-of-bbo-in-adult-subjects-with-non-small-cell-lung-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2024-05-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-22",
            "studyFirstSubmitQcDate": "2024-04-01",
            "studyFirstPostDateStruct": {
                "date": "2024-04-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A first in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-8520, a KRAS G12C (ON) inhibitor, single agent and in combination with pembrolizumab in patients with advanced non-small cell lung cancer",
            "detailedDescription": "This is an open-label, multi-center Phase 1a/1b study designed to evaluate the safety, tolerability, preliminary antitumor activity, and PK of BBO-8520 as a single agent and in combination with pembrolizumab in patients with KRAS (Kirsten rat sarcoma) G12C mutant non-small cell lung cancer. The study includes dose escalation phase, and expansion phase"
        },
        "conditionsModule": {
            "conditions": [
                "Non-small Cell Lung Cancer",
                "Metastatic Non-Small Cell Lung Cancer",
                "NSCLC",
                "KRAS G12C",
                "Metastatic Lung Cancer",
                "Advanced Lung Carcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Phase 1a: sequential/parallel, Phase 1b: parallel",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 160,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1a - Dose Escalation/Dose Finding Monotherapy",
                    "type": "EXPERIMENTAL",
                    "description": "Participants enrolled in this cohort will receive BBO-8520 (different dose levels will be evaluated) once a day (QD) as monotherapy",
                    "interventionNames": [
                        "Drug: BBO-8520"
                    ]
                },
                {
                    "label": "Cohort 1b - Dose Escalation/Dose Finding Combination Therapy",
                    "type": "EXPERIMENTAL",
                    "description": "Participants enrolled in this cohort will receive BBO-8520 (different dose levels will be evaluated) once a day (QD) in combination with pembrolizumab infusion (IV)",
                    "interventionNames": [
                        "Drug: BBO-8520",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "Cohort 2a - Dose Expansion Monotherapy",
                    "type": "EXPERIMENTAL",
                    "description": "Participants enrolled in this cohort will receive BBO-8520 once a day (QD) as monotherapy",
                    "interventionNames": [
                        "Drug: BBO-8520"
                    ]
                },
                {
                    "label": "Cohort 2b - Dose Expansion Combination Therapy",
                    "type": "EXPERIMENTAL",
                    "description": "Participants enrolled in this cohort will receive BBO-8520 once a day (QD) in combination with pembrolizumab infusion (IV)",
                    "interventionNames": [
                        "Drug: BBO-8520",
                        "Drug: Pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BBO-8520",
                    "description": "Participants will receive assigned dose of BBO-8520 orally (PO), QD",
                    "armGroupLabels": [
                        "Cohort 1a - Dose Escalation/Dose Finding Monotherapy",
                        "Cohort 1b - Dose Escalation/Dose Finding Combination Therapy",
                        "Cohort 2a - Dose Expansion Monotherapy",
                        "Cohort 2b - Dose Expansion Combination Therapy"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "Patients will receive IV pembrolizumab",
                    "armGroupLabels": [
                        "Cohort 1b - Dose Escalation/Dose Finding Combination Therapy",
                        "Cohort 2b - Dose Expansion Combination Therapy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse Events",
                    "description": "Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)",
                    "timeFrame": "approximately 3 years"
                },
                {
                    "measure": "Dose-limiting toxicities (DLTs)",
                    "description": "Number of participants with dose limiting toxicities",
                    "timeFrame": "approximately 3 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "To evaluate preliminary antitumor activity of BBO-8520",
                    "description": "Progression-free survival (PFS) per (RECIST v1.1)",
                    "timeFrame": "approximately 3 years"
                },
                {
                    "measure": "To evaluate preliminary antitumor activity of BBO-8520",
                    "description": "Duration of response (DOR) per (RECIST v1.1)",
                    "timeFrame": "approximately 3 years"
                },
                {
                    "measure": "Overall Survival (OS)",
                    "timeFrame": "approximately 3 years"
                },
                {
                    "measure": "To characterize the pharmacokinetics (PK) of BBO-8520",
                    "description": "Area under the curve (AUC)",
                    "timeFrame": "approximately 3 years"
                },
                {
                    "measure": "To characterize the pharmacokinetics (PK) of BBO-8520",
                    "description": "Peak plasma drug concentration (Cmax)",
                    "timeFrame": "approximately 3 years"
                },
                {
                    "measure": "To characterize the pharmacokinetics (PK) of BBO-8520",
                    "description": "Time to Cmax (Tmax)",
                    "timeFrame": "approximately 3 years"
                },
                {
                    "measure": "To characterize the pharmacokinetics (PK) of BBO-8520",
                    "description": "Half life (T1/2)",
                    "timeFrame": "approximately 3 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically documented locally advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation\n* Measurable disease by RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1\n\nExclusion Criteria:\n\n* Patients with malignancy within the last 2 years as specified in the protocol\n* Patients with untreated brain metastases\n* Patients with known hypersensitivity to BBO-8520 or its excipients\n* For Cohorts 2a and 2b:\n* Patients with a known hypersensitivity to pembrolizumab or its excipients\n* Patients with active autoimmune disease of history of autoimmune disease that might recur\n* Patients with a history of interstitial lung disease/pneumonitis that required steroids, or current interstitial lung disease/pneumonitis\n\nOther inclusion/exclusion criteria may apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "TheRas",
                    "role": "CONTACT",
                    "phone": "650-391-9740",
                    "email": "onkoras-101ct.gov@bridgebiooncology.com"
                }
            ],
            "locations": [
                {
                    "facility": "Norwalk Hospital",
                    "status": "RECRUITING",
                    "city": "Norwalk",
                    "state": "Connecticut",
                    "zip": "06850",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.1176,
                        "lon": -73.4079
                    }
                },
                {
                    "facility": "University of Kansas Medical Center",
                    "status": "RECRUITING",
                    "city": "Kansas City",
                    "state": "Kansas",
                    "zip": "66205",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.11417,
                        "lon": -94.62746
                    }
                },
                {
                    "facility": "Cleveland Clinic",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "SCRI Oncology Partners",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "Peninsula & South Eastern Hematology and Oncology Group (PAS)",
                    "status": "RECRUITING",
                    "city": "Frankston",
                    "state": "Victoria",
                    "zip": "3199",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -38.14458,
                        "lon": 145.12291
                    }
                },
                {
                    "facility": "Peter MacCallum Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "state": "Victoria",
                    "zip": "3051",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}